The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).
Daniel C. Cho
No relevant relationships to disclose
Jeffrey Alan Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Mario Sznol
Consultant or Advisory Role - Bristol-Myers Squibb; Genesis Pharmaceuticals
Michael S. Gordon
Consultant or Advisory Role - Genentech
Research Funding - Genentech/Roche
Antoine Hollebecque
No relevant relationships to disclose
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
David F. McDermott
Consultant or Advisory Role - Genentech/Roche
Jean-Pierre Delord
No relevant relationships to disclose
Ina Park Rhee
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche
Ahmad Mokatrin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche
Marcin Kowanetz
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Roel Peter Funke
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Gregg Daniel Fine
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche
Thomas Powles
No relevant relationships to disclose